These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 31494141)

  • 1. Optogenetic and chemogenetic therapies for epilepsy.
    Walker MC; Kullmann DM
    Neuropharmacology; 2020 May; 168():107751. PubMed ID: 31494141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DREADDs suppress seizure-like activity in a mouse model of pharmacoresistant epileptic brain tissue.
    Avaliani N; Andersson M; Runegaard AH; Woldbye D; Kokaia M
    Gene Ther; 2016 Oct; 23(10):760-766. PubMed ID: 27416078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term chemogenetic suppression of spontaneous seizures in a mouse model for temporal lobe epilepsy.
    Desloovere J; Boon P; Larsen LE; Merckx C; Goossens MG; Van den Haute C; Baekelandt V; De Bundel D; Carrette E; Delbeke J; Meurs A; Vonck K; Wadman W; Raedt R
    Epilepsia; 2019 Nov; 60(11):2314-2324. PubMed ID: 31608439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The path from scientific discovery to cures for epilepsy.
    Carvill GL; Dulla CG; Lowenstein DH; Brooks-Kayal AR
    Neuropharmacology; 2020 May; 167():107702. PubMed ID: 31301334
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term chemogenetic suppression of seizures in a multifocal rat model of temporal lobe epilepsy.
    Goossens MG; Boon P; Wadman W; Van den Haute C; Baekelandt V; Verstraete AG; Vonck K; Larsen LE; Sprengers M; Carrette E; Desloovere J; Meurs A; Delbeke J; Vanhove C; Raedt R
    Epilepsia; 2021 Mar; 62(3):659-670. PubMed ID: 33570167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemogenetic Seizure Control with Clozapine and the Novel Ligand JHU37160 Outperforms the Effects of Levetiracetam in the Intrahippocampal Kainic Acid Mouse Model.
    Desloovere J; Boon P; Larsen LE; Goossens MG; Delbeke J; Carrette E; Wadman W; Vonck K; Raedt R
    Neurotherapeutics; 2022 Jan; 19(1):342-351. PubMed ID: 34862591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Designer receptor technology for the treatment of epilepsy.
    Lieb A; Weston M; Kullmann DM
    EBioMedicine; 2019 May; 43():641-649. PubMed ID: 31078519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms of action of currently used antiseizure drugs.
    Sills GJ; Rogawski MA
    Neuropharmacology; 2020 May; 168():107966. PubMed ID: 32120063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optogenetic approaches to treat epilepsy.
    Wykes RC; Kullmann DM; Pavlov I; Magloire V
    J Neurosci Methods; 2016 Feb; 260():215-20. PubMed ID: 26072246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optogenetic dissection of ictogenesis: in search of a targeted anti-epileptic therapy.
    Lillis KP; Staley KJ
    J Neural Eng; 2018 Aug; 15(4):041001. PubMed ID: 29536948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Practical Considerations for the Use of DREADD and Other Chemogenetic Receptors to Regulate Neuronal Activity in the Mammalian Brain.
    Aldrin-Kirk P; Björklund T
    Methods Mol Biol; 2019; 1937():59-87. PubMed ID: 30706390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optogenetics and Chemogenetics.
    Vlasov K; Van Dort CJ; Solt K
    Methods Enzymol; 2018; 603():181-196. PubMed ID: 29673525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microbial Proteins as Novel Industrial Biotechnology Hosts to Treat Epilepsy.
    Amtul Z; Aziz AA
    Mol Neurobiol; 2017 Dec; 54(10):8211-8224. PubMed ID: 27905012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Research advances in basic mechanisms of seizures and antiepileptic drug action.
    Lasoń W; Chlebicka M; Rejdak K
    Pharmacol Rep; 2013; 65(4):787-801. PubMed ID: 24145073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An optogenetic approach in epilepsy.
    Kokaia M; Andersson M; Ledri M
    Neuropharmacology; 2013 Jun; 69():89-95. PubMed ID: 22698957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemogenetics revealed: DREADD occupancy and activation via converted clozapine.
    Gomez JL; Bonaventura J; Lesniak W; Mathews WB; Sysa-Shah P; Rodriguez LA; Ellis RJ; Richie CT; Harvey BK; Dannals RF; Pomper MG; Bonci A; Michaelides M
    Science; 2017 Aug; 357(6350):503-507. PubMed ID: 28774929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The first structure-activity relationship studies for designer receptors exclusively activated by designer drugs.
    Chen X; Choo H; Huang XP; Yang X; Stone O; Roth BL; Jin J
    ACS Chem Neurosci; 2015 Mar; 6(3):476-84. PubMed ID: 25587888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is the antiparasitic drug ivermectin a suitable candidate for the treatment of epilepsy?
    Löscher W
    Epilepsia; 2023 Mar; 64(3):553-566. PubMed ID: 36645121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DREADDs in Epilepsy Research: Network-Based Review.
    Mueller JS; Tescarollo FC; Sun H
    Front Mol Neurosci; 2022; 15():863003. PubMed ID: 35465094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Why we urgently need improved seizure and epilepsy therapies for children and neonates.
    Pressler RM; Lagae L
    Neuropharmacology; 2020 Jun; 170():107854. PubMed ID: 31751548
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.